Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Long-Term Debt Repayments (2019 - 2020)

Avidity Biosciences (RNA) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $4.0 million as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Long-Term Debt Repayments changed N/A year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Mar 2021, changed N/A, and an annual FY2020 reading of $4.7 million, up 67.25% over the prior year.
  • Long-Term Debt Repayments was $4.0 million for Q2 2020 at Avidity Biosciences, up from $700000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $4.0 million in Q2 2020 and bottomed at $700000.0 in Q3 2019.